Nvidia Options Price in $280 Billion Earnings Swing 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Tesla Raises Cybertruck Prices by $5,000 in US 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Trump Buys SpaceX Shares After Record IPO 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Add as a preferred source on Google
EMERYVILLE, Calif., April 26, 2018 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.
Investor Conference Call and Webcast
The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for replay until June 3, 2018.
About Adamas Pharmaceuticals, Inc.
Adamas’ goal is to create and commercialize a new generation of medicines intended to lessen the burden of chronic neurologic diseases on patients, caregivers and society using its deep understanding of time-dependent biology. The company is focused on the commercial launch of GOCOVRI™ (amantadine) extended release capsules (previously ADS-5102), the first and only medicine approved by the U.S. Food and Drug Administration for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, and delivering on its pipeline of differentiated investigational programs. Those programs include: ADS-5102 in development for the treatment of multiple sclerosis walking impairment; and ADS-4101, a high-dose, modified release lacosamide in development for the treatment of partial onset seizures in patients with epilepsy. For more information about Adamas and its unique approach to developing medicines based on time-dependent biology, please visit www.adamaspharma.com.
Contact: Ashleigh Barreto Director, Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. 510-450-3567 [email protected]
